ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Serum L-ornithine-derived polyamines as indicators of Parkinson disease progression.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Polyamine metabolic enzyme SAT1 remodels the neuronal transcriptome and rescues α-synuclein toxicity in Drosophila.Amino acids · 2026Article
- Polyamine metabolic enzyme SAT1 remodels the neuronal transcriptome and rescues α-synuclein toxicity in Drosophila.Research square · 2026Article
- Hyperprolactinemia and Brain Health: Exploring the Gut-Brain Axis and Therapeutic Strategies.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prior studies reported that biospecimen concentrations of L-ornithine-derived polyamines (ODPAs) and their metabolites differentiated Parkinson disease (PD) from healthy controls. We investigated ODPA metabolism in CSF and serum specimens from well-characterized, unmedicated PD patients to explore correlations with disease severity, progression, and PD clinical subtypes using data from Unified PD Rating Scale (UPDRS) assessments. We developed targeted assays for L-ornithine and the ODPAs putrescine, spermine, spermidine, and the polyamine metabolites N
Indexed as
Identifiers
41182351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.